Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Glycanostics S R O has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners but 2 distinct art units, indicating that at least one art unit handles more than one examiner assignment.
TRAN, CHAU NGUYEN BICH is the busiest examiner, with 1 pending matter. Response preparation should track examiner-specific positions while also accounting for the shared art-unit structure.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, CHAU NGUYEN BICH | 1 | 31.6% | +45.2% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691611 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | TRAN, CHAU NGUYEN BICH | — |
| 18681392 | STANDARD FOR GLYCOPROFILING OF PROTEINS | EVANS, CHRISTOPHER RYAN | — |
| 17041816 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691611 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | TRAN, CHAU NGUYEN BICH | — |
| 18681392 | STANDARD FOR GLYCOPROFILING OF PROTEINS | EVANS, CHRISTOPHER RYAN | — |
| 17041816 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | FRITCHMAN, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1677 | 2 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691611 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | TRAN, CHAU NGUYEN BICH | 1677 | §101§102§103DP | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18681392 | STANDARD FOR GLYCOPROFILING OF PROTEINS | EVANS, CHRISTOPHER RYAN | 1677 | §101§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 17041816 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | — | Pending | Sep 25, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlycanostics S R O has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Chau Nguyen Bich Tran has the most, with 1 of Glycanostics S R O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
